THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preliminary results from clinical trials suggest that 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors may help prevent acute renal allograft rejection. However, the mechanism for this putative effect of 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors, and whether it is independent of lipid-lowering per SE are unknown. METHODS: Immediately after renal transplantation we randomly allocated (proportioned 2:1:2) patients to: 1) simvastatin (10 mg/day, n=53), 2) simvastatin placebo plus gemfibrozil (dose adjusted for renal function, n=36), and 3) simvastatin placebo (n=52). RESULTS: Simvastatin, but not gemfibrozil, reduced total and low density lipoprotein cholesterol during the first 90 days posttransplant. There were no major adverse effects of therapy. However, there were no effects of treatment on acute rejection. Indeed, survival free of acute rejection at 90 days was 72% in the simvastatin group, 72% in the gemfibrozil group, and 77% in the placebo control group (P=0.771). A post hoc power analysis suggested that there was only a 7.5% chance that a true effect of simvastatin on acute rejection (versus placebo) was not detected, and a 2.5% chance that an effect of gemfibrozil on acute rejection (versus placebo) was not detected in this study. CONCLUSION: Lipid-lowering agents may not reduce the incidence of acute renal allograft rejection. However, additional studies are needed to confirm this observation. In the mean time, many if not most renal transplant recipients should be treated with HMG-CoA reductase inhibitors starting early posttransplant to prevent cardiovascular disease complications. The results of this study suggest that starting lipid-lowering therapy immediately after renal transplantation is both safe and effective in lowering total and low density lipoprotein cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301 · cited 6×
“The acute rejection after renal transplantation is predominately a tubulointerstitial disease, and the characteristic vascular lesions seen after heart transplantation are more common and usually more severe than those seen after renal transplantation (5,6).”
BackgroundResultInfluentialWenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444 · cited 5×
“The acute rejection after renal transplantation is predominately a tubulointerstitial disease, and the characteristic vascular lesions seen after heart transplantation are more common and usually more severe than those seen after renal transplantation (5,6).”
BackgroundInfluential
Cited by
Cardiovascular Toxicities of Immunosuppressive Agents
Miller, L. W. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.20902.x · Cited by 467
Cardiovascular Complications After Renal Transplantation and Their Prevention
Ojo, A. O. (2006) · Transplantation · doi:10.1097/01.tp.0000235527.81917.fe · Cited by 450
Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates
Lentine, K. L., Costa, S. P., Weir, M. R., Robb, J. F., Fleisher, L. A., Kasiske, B. L., Carithers, R. L., Ragosta, M., Bolton, K., Auerbach, A. D., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.05.008 · Cited by 399
Self-citationPalmer, S. C., Craig, J. C., Navaneethan, S. D., Tonelli, M., Pellegrini, F., & Strippoli, G. F. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00007 · Cited by 359
Anti-inflammatory and immunomodulatory effects of statins
Blanco-Colio, L. M., Tuñón, J., Martín-Ventura, J. L., & Egido, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00744.x · Cited by 347
Metadata
- Authors
- Kasiske, B. L., Heim-Duthoy, K. L., Singer, G. G., Watschinger, B., Germain, M. J., & Bastani, B.
- Venue
- Transplantation
- Published
- 2001-07
- Volume
- 72
- Issue
- 2
- Pages
- 223-227
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2037198165
- Cited by
- 94
- References
- 2
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2. https://app.cochat.ai/papers/10.1097/00007890-200107270-00009
- The paper
- Kasiske, B. L., Heim-Duthoy, K. L., Singer, G. G., Watschinger, B., Germain, M. J., & Bastani, B. (2001). THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2. Transplantation. https://doi.org/10.1097/00007890-200107270-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.